Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 08/07/2017
Entire Document
 
 

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2017 and 2016

 

The following table summarizes our results of operations for the three months ended June 30, 2017 and 2016 (in thousands):

 

   Three Months Ended June 30,   
   2017  2016  Period-to-Period Change
          
Operating expenses:               
Research and development  $3,891   $5,241   $(1,350)
General and administrative   2,095    2,613    (518)
Total operating expenses   5,986    7,854    (1,868)
Loss from operations   (5,986)   (7,854)   1,868 
Other income (expense):               
Investment income   46    53    (7)
Other income (expense), net   332    (104)   436 
Total other income (expense)   378    (51)   429 
Net Loss  $(5,608)  $(7,905)  $2,297 

 

 Research and Development Expenses. The following table identifies research and development expenses on both an external and internal basis for the three months ended June 30, 2017 and 2016 (in thousands):

 

   Three Months Ended June 30,  Period-to-Period
   2017  2016  Change
          
External vonapanitase research and development expenses  $2,651   $3,859   $(1,208)
Internal research and development expenses   1,240    1,382    (142)
Total research and development expenses  $3,891   $5,241   $(1,350)

 

During the three months ended June 30, 2017, our total research and development expenses decreased by $1.4 million primarily due to a decrease of $1.2 million in our manufacturing pre-validation and validation efforts in the three months ended June 30, 2017 as compared to the three months ended June 30, 2016.

 

General and Administrative Expenses. During the three months ended June 30, 2017, our total general and administrative expenses were $0.5 million lower as compared to the three months ended June 30, 2016 primarily due to decreased overhead and personnel expenses of $0.6 million offset by an increase in expenses associated with being a public company of $0.1 million.

 

Investment Income. During the three months ended June 30, 2017, investment income decreased by an immaterial amount.

 

Other Income (Expense), Net. During the three months ended June 30, 2017, other income (expense), net changed by $0.4 million primarily due to foreign currency remeasurement gain of $0.3 million for cash denominated in Swiss Francs and the change in the three months ended June 30, 2016 in the fair value associated with the forward foreign currency contracts we entered into in the second quarter of 2015. As of December 31, 2016, all forward foreign currency contracts had been settled and are no longer outstanding.

 

 19